Jiahua is a leading independent Chinese Specialty Chemicals manufacturing group. The HQ and R & D Centre are based in Shanghai. The main industries currently supplied are Urethanes, Surfactants and Construction Chemicals. They have offices and China, Dubai, Philadelphia and Newcastle.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. Their mission is to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Iksuda Therapeutics is a developer of next generation Antibody Drug Conjugates (ADCs) for the treatment of difficult to treat solid tumours including ovarian, lung and breast cancers. By developing technology-based solutions to issues currently limiting clinical success with ADCs, Iksuda has been able to further develop its own portfolio of drug candidates demonstrating a significant improvement over current clinical approaches and specifically targeting solid tumours with high unmet needs.
The Northern Retrieval Registry (NRR) is an organisation dedicated to improving patient healthcare through the study of devices which have been removed from the body ("explants"). The NRR combines decades of medical, surgical and engineering experience to achieve these aims.
Highly experienced in synthetic organic chemistry and medicinal chemistry, their medicinal chemists have involved in several drug research projects with pharma and academic collaborators. Additionally, their company scientific director Professor Bernard T Golding published more than 500 publications, his main research areas include synthetic methodology, enzyme mechanisms, drug design and mechanistic toxicology.
NewChem is an innovative chemical company which specialises in commercial applications for organic chemistry. NewChem Technologies works with industry and academia to develop and deliver new breakthrough products in synthetic chemistry. They work with a wide variety of companies in fields ranging from pharmaceuticals, diagnostics, biotechnology, veterinary science and agrochemicals. They emerged as a spin-out from Newcastle University School of Chemistry and retains the culture of curiosity and intellectual enquiry inherited from our academic roots.
Alcyomics is a Newcastle based unique pre-clinical service provider using Skimune®, non-artificial human skin explants for predicting adverse immune reactions as well as determining efficacy of novel compounds including pharmaceuticals, chemicals and cosmetics.
Our mission at Alcyomics is to provide novel solutions for pre-clinical drug safety and efficacy testing for therapeutics including cellular therapies which is also extended to the chemical and cosmetic industries. As a Service provider Alcyomics aspires to take the lead in providing unique screening services using human in vitro skin explant assays enabling more cost-effective commercialisation of products and or drugs. Alcyomics development pipeline includes drug discovery disease modelling for the identification of novel drug targets.
We also offer a consultancy service of how the pre-clinical data can be used to assist clinical trial development such as dose response and assist in developing stratified medicine/ precision medicine approaches to patient selection. Alcyomics technology is also a reliable alternative to animal testing for safety and potency assessment of novel compounds.
A leading provider of DNA-based relationship testing and human identity services. NorthGene provides genetic testing to private individuals, family law practices, local authority and government agencies including Embassies and Coroners. The Company has over 25 years’ experience of delivering high quality services in a tightly regulated industry and carries the highest level of laboratory accreditations from The Ministry of Justice and UK regulatory authorities. They also offer research and development services for genetic testing and molecular diagnostics to universities, forensic science services and public health bodies.
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We use alginate hydrogels to encapsulate biological products, protecting them from biochemical and physical damage during storage and shipment. We can hold cells and tissues at room temperature for up to two weeks, effectively placing them into a state of hibernation.
Demuris has a large portfolio of drug projects and state-of-the-art platform technologies in natural product discovery, design and production. The rise in drug resistant pathogens is causing serious health concerns and an increasing economic burden. There is a growing demand for new agents to treat these evolving diseases. Demuris is developing a suite of new antibiotic compounds active in key areas of unmet medical need. They have recently secured £342,160 from Innovate UK to continue to develop a new antibiotic to treat drug resistant forms of the disease (known as MDR-TB).
The Biosphere was awarded £8.6m from the Government’s Local Growth Fund through the North East Local Enterprise Partnership (LEP) along with £4.96m from the European Regional Development Fund.
The Biosphere owned by Newcastle City Council has received £4.96m from the England European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020. The Ministry for Housing, Communities and Local Government (and in London the intermediate body Greater London Authority) is the Managing Authority for the European Regional Development Fund.
Established by the European Union, the European Regional Development Fund helps local areas stimulate their economic development by investing in projects which will support innovation, businesses, create jobs and local community regenerations. For more information visit https://www.gov.uk/european-growth-funding.
The Biosphere is part funded by the North East Local Growth Fund from HM Government, administered by the North East Local Enterprise Partnership. The Local Growth Fund is supporting major capital investments to promote innovation, economic and skills infrastructure and sustainable transport as part of the North East Growth Deal. The North East LEP works to make the North East a place where more businesses invest, grow and prosper. For more information visit www.northeastlep.co.uk